- Home
- ABUS vs VIR Comparison
ABUS vs VIR Comparison
Compare ABUS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- VIR
- Stock Information
- Founded
- ABUS 2005
- VIR 2016
- Country
- ABUS United States
- VIR United States
- Employees
- ABUS N/A
- VIR N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- ABUS Health Care
- VIR Health Care
- Exchange
- ABUS Nasdaq
- VIR Nasdaq
- Market Cap
- ABUS 711.2M
- VIR 706.4M
- IPO Year
- ABUS N/A
- VIR 2019
- Fundamental
- Price
- ABUS $4.46
- VIR $6.10
- Analyst Decision
- ABUS Strong Buy
- VIR Strong Buy
- Analyst Count
- ABUS 2
- VIR 11
- Target Price
- ABUS $5.00
- VIR $25.73
- AVG Volume (30 Days)
- ABUS 930.7K
- VIR 1.5M
- Earning Date
- ABUS 11-10-2025
- VIR 11-05-2025
- Dividend Yield
- ABUS N/A
- VIR N/A
- EPS Growth
- ABUS N/A
- VIR N/A
- EPS
- ABUS N/A
- VIR N/A
- Revenue
- ABUS $15,416,000.00
- VIR $19,000,000.00
- Revenue This Year
- ABUS $138.02
- VIR N/A
- Revenue Next Year
- ABUS N/A
- VIR $15.25
- P/E Ratio
- ABUS N/A
- VIR N/A
- Revenue Growth
- ABUS 53.23
- VIR N/A
- 52 Week Low
- ABUS $2.71
- VIR $4.16
- 52 Week High
- ABUS $5.10
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- ABUS 54.42
- VIR 57.35
- Support Level
- ABUS $4.26
- VIR $5.75
- Resistance Level
- ABUS $4.61
- VIR $6.44
- Average True Range (ATR)
- ABUS 0.20
- VIR 0.34
- MACD
- ABUS -0.01
- VIR -0.02
- Stochastic Oscillator
- ABUS 65.45
- VIR 59.04
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.